Thank you for permitting us to share in the care of your patients.
We continue to consistently exceed the service and patient care expectations of your patients. We do so by investing in staff education and new treatment modalities. We maintain a warm and pleasing environment for your patients. We strive to be available and accessible. We will continually work to insure respectful communication with every patient and are aware that it is how we serve that creates your patient experience.
Transfer of patients is always determined with patient safety in mind. The post-op report will release your patient back to your care when they are happy. In most cases this is one-to-two weeks after surgery.
We continue to provide iLASIK, Advanced Technology Lifestyle Lens Implants, and Cataract Surgery. Our staff are experts in preparing patients for surgery and assisting in pre-authorization from insurance plans. Please notify me whenever you sense your patients experience does not meet your expectations. We’ll be on it immediately.
I look forward to working with you in the upcoming year!
With warm regards,
In our quest to provide better care for your patients, we began performing dropless cataract surgery after January 1st of 2016. As you know, some patients still need drops for inherent conditions such as epiretinal membrane, diabetic macular edema, etc.Over 90% of patients need no eyedrops after surgery, but as many as one in ten may develop “rebound inflammation” after the intravitreal steroid effect wears off.Â These patients typically present 3 weeks out from surgery with iritis symptoms such as redness, irritation or photophobia.Â They respond well to initiation of topical steroids.Â They may call the office (invariably Friday at 4:30PM!) and we call in a prescription for Pred Forte and have them schedule as soon as convenient, usually within a couple of days.
We are moving up our 1 month follow-up appointment to 3 weeks and suggest you do this also. Please inform us if you have a patient with rebound inflammation (by way of your post-opÂ form), as we are trying to assess the percentage of patients who have “rebound inflammation”.Â Nationally others are reporting 9%, but we are seeing about 6%.Â Our patient population is 95%+ Caucasian which may skew the data, as darkly pigmented patients are thought to be more apt to get inflammation.Â In any case, we feel having to start drops in less than 10% of cases is a small price to pay to avoid drops for 90% of patients, and decreasing the risk of endophthalmitis from 1:2000 to 1:20,000.
Best wishes, Bruce, Bruce and Natalia